Virios Therapeutics (NASDAQ:VIRI) Trading 15.1% Higher - What's Next?

Key Points

• Virios Therapeutics shares rose by 15.1% to $6.18, despite trading volume dropping 93% from the average session.
• The company's lead candidate, IMC-1, aims to treat fibromyalgia through a combination of famciclovir and celecoxib.
• Virios Therapeutics has a market capitalization of $119.01 million and a negative price-to-earnings ratio of -22.89.

Virios Therapeutics, Inc. (NASDAQ:VIRI - ) shares traded up 15.1% on Tuesday . The stock traded as high as $6.20 and last traded at $6.18. 72,489 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 1,049,645 shares. The stock had previously closed at $5.37.

Virios Therapeutics Stock Up 15.1%

The company's fifty day simple moving average is $5.30 and its two-hundred day simple moving average is $4.98. The company has a market capitalization of $119.01 million, a price-to-earnings ratio of -22.89 and a beta of 1.58.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.